Meghna Jani MRCP, PhD

Meghna moved to Manchester to undertake specialty training in medicine. During her rheumatology specialty training she undertook an MSc in Clinical Rheumatology and successfully obtained an MRC Clinical Pharmacology & Therapeutics fellowship to undertake a PhD on immunogenicity in response to biologic therapies (awarded Dec 2015). Her PhD research focused on examining biomarkers of treatment response, pharmacoepidemiology as well as establishing and coordinating the OUTPASS study, a multi-centre national study investigating treatment response to biologics in psoriatic arthritis.

She was awarded the European League Against Rheumatism (EULAR) abstract award for basic science in 2014, the British Medical Association (BMA) Doris Hillier Award (£50,000) in 2016 to investigate the role of biomarkers in the prediction of serious adverse events to biologic drugs during her clinical lectureship and the Royal Society of Medicine Eric Bywaters Prize for research in 2017. She has also obtained a project grant from the MRC Confidence in Concept Scheme to develop a predictive tool for subsequent biologic response in rheumatoid arthritis patients treated with TNF-inhibitors.

Other current work includes investigation of opioid safety as part of large international collaboration. She was selected to be a fellow member on the EULAR Task force for recommendations for management of rheumatoid arthritis with synthetic and biological DMARDs 2016. In addition she is the trainee representative on the Arthritis Research UK Clinical Study Group for Inflammatory Arthritis Steering Group and the EMEUNET (Emerging EULAR Network) Education Subgroup Leader.